Netupitant
- Generic Name
- Netupitant
- Brand Names
- Akynzeo
- Drug Type
- Small Molecule
- Chemical Formula
- C30H32F6N4O
- CAS Number
- 290297-26-6
- Unique Ingredient Identifier
- 7732P08TIR
- Background
Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.
- Indication
用于治疗和预防化疗引起的急性和延迟性恶心、呕吐。
- Associated Conditions
- Acute chemotherapy-induced nausea and vomiting, Delayed chemotherapy-induced nausea and vomiting
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath